Hypoglycemia and the Mineralocorticoid Receptor

• Status: Completed
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to look at whether blockade of the mineralocorticoid receptor will result in changes in the cardiovascular and inflammatory response to hypoglycemia.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Brigham and Women's Hospital
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH); Robert Wood Johnson Foundation
• Treatments: Eplerenone; Mineralocorticoids; Spironolactone

Criteria

Inclusion Criteria:

• Healthy volunteers

• Males and females age 18 to 40 years

Exclusion Criteria:

• Pregnancy

• Lactation

• Menopause

• Any medical condition other than treated hypothyroidism.

• Alcoholism

• Active tobacco use

• In all subjects, any individuals on oral, injected, inhaled or topical corticosteroids within the last year or oral contraceptives within the past 3 months will be excluded.

• Use of medications other than physiological thyroxine replacement

• Serum potassium >5.0 mmol/L

• Estimated glomerular filtration rate < 60 mL/min